Word: patients
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...cells: too many copies of a gene known as HER-2/neu. This gene makes a protein that helps relay the signal telling cells to divide. Having too much of it is associated with an especially rampaging, hard-to-treat cancer. Once this form of breast cancer metastasizes, a patient typically has just six to 12 months to live...
...story about preliminary data on laboratory animals spiral so completely out of control? The key is Kolata's piece in the Times and the prominent placement her editors gave it. "Within a year," she began, "if all goes well, the first cancer patient will be injected with two new drugs that can eradicate any type of cancer, with no obvious side effects and no drug resistance--in mice." It was a sentence that couldn't help grabbing readers' attention--despite those critical two words, "in mice"--and holding it throughout the rest of the story...
...cartilage to fungi to the notorious sedative thalidomide--Folkman found one compound after another that exhibited anti-angiogenic properties. But none of them was as effective as he wanted it to be. Then he remembered something that surgeons had often observed: that taking out one big tumor from a patient seems to trigger the growth of lots of smaller ones. Could it be that tumors secrete a substance that inhibits the growth of rival tumors' blood vessels...
...York City, Dr. Mark Malkin is working with a substance that targets a receptor for another growth factor called PDGF (platelet-derived growth factor). This receptor studs the surfaces of cells in certain ovarian, prostate, lung and brain tumors. Malkin has been testing the drug, SU101, on patients with an extraordinarily deadly brain tumor called glioblastoma. Median survival for a patient found to have this cancer is 14 months...
...drug, manufactured by Sugen, appears to slow or arrest tumor growth in about a third of glioblastoma patients, but it's too soon to say how long the benefits will last. Side effects appear to be mild. "We have one patient who's been on it for two years and three months," says Malkin. "His tumor is still there, but it's stable. He's alive; he's at work. For someone with recurrent glioblastoma, that's remarkable...